Bailard’s Enanta Pharmaceuticals ENTA Stock Holding History

Bailard’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-67,000	Closed	-$3.01M	–	256
2015 Q2	$3.01M	Sell	67,000 -33,000	-33%	-$1.28M	0.47%	36
2015 Q1	$3.06M	Buy	100,000 +25,500	+34%	+$992K	0.42%	34
2014 Q4	$3.79M	Sell	74,500 -17,000	-19%	-$761K	0.54%	25
2014 Q3	$3.62M	Hold	91,500	–	–	0.56%	27
2014 Q2	$3.94M	Buy	91,500 +17,194	+23%	+$656K	0.61%	24
2014 Q1	$2.97M	Sell	74,306 -16,560	-18%	-$602K	0.47%	28
2013 Q4	$2.48M	Sell	90,866 -39,600	-30%	-$960K	0.4%	31
2013 Q3	$2.99M	Buy	+130,466	New	+$2.49M	0.57%	25

Other funds holding ENTA

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Bailard's ENTA Position: Q3 2015 in Review

Bailard sold out of Enanta Pharmaceuticals (ENTA) in Q3 2015, closing a stake of 67,000 shares — an estimated $3.01M sold.

Bailard first reported a position in ENTA in Q3 2013 and held it in 8 quarters. The position peaked at $3.94M in Q2 2014. 144 funds tracked by Wall St. Rank hold ENTA as of Q3 2015.

Bailard reported no remaining Enanta Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Bailard sold 67,000 Enanta Pharmaceuticals shares in Q3 2015, an estimated $3.01M.
Bailard first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Bailard's Enanta Pharmaceuticals position peaked at $3.94M in Q2 2014.
144 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2015.

Based on Bailard's 13F filing for Q3 2015, filed 13 Nov 2015.